GEETHU PHILIP: Open Payments
NPI 1992467849 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,421 in 57 payments from 11 companies in 2025. Trend: 2023 $720 · 2024 $884 · 2025 $1,421
Food & beverage: $1,421
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 17 | $606 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $204 |
| Gilead Sciences, Inc. | 10 | $198 |
| ABBVIE INC. | 10 | $172 |
| Intercept Pharmaceuticals, Inc. | 3 | $66 |
| Ipsen Biopharmaceuticals, Inc | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Eisai Inc. | 1 | $28 |
| ORPHALAN INC | 1 | $27 |
| Novo Nordisk Inc | 1 | $17 |
Products named: REZDIFFRA, XIFAXAN, MAVYRET, OCALIVA, IQIRVO, LIVTENCITY, Lenvima, CUVRIOR.
Industry payments across TX — which companies pay providers there.
